久久久久免费_精品国产乱码久久久久久久软件_欧美一区亚洲一区_国产一区二区三区高清在线观看_欧美日在线观看_成人网av

美國(guó)Molecular Insight Pharmaceuticals?
Molecular Insight醫(yī)藥公司是一家突出的私營(yíng)生物制藥公司，致力于專(zhuān)利技術(shù)的改良，以開(kāi)發(fā)新型的分子成像藥物。這些產(chǎn)品通過(guò)在分子水平上使疾病進(jìn)程更加清晰而提高疾病的診療水平。公司總部在美國(guó)馬薩諸塞州劍橋市，已建立強(qiáng)大的產(chǎn)品管線，主要集中在涉及心血管、感染、腫瘤及神經(jīng)領(lǐng)域的發(fā)展中的主要成像市場(chǎng)。

Molecular Insight Pharmaceuticals is a clinical-stage biopharmaceutical company and a pioneer in the emerging field of molecular medicine. The Company is focused on the discovery and development of therapeutic radiopharmaceuticals and targeted molecular imaging agents for use in oncology and cardiology.

Molecular Insight takes advantage of specific disease-related changes at the cellular level that occur in cancers in order to target the delivery of therapeutic radiopharmaceuticals to treat tumor cells that have spread throughout the body. The selective accumulation of radiotherapeutic compounds in cancers allows direct tumor killing while sparing normal tissues of serious toxicity. Targeted radiotherapy for widespread cancers brings a well understood and successful therapy (radiation) to the treatment of late-stage cancers. Since the ‘therapy’ is localized in the tumors and the mass of nonradioactive compound is very low, side effects may be less severe than conventional chemotherapy. Due to the exquisite sensitivity of radiopharmaceutical molecular imaging (nuclear medicine), it is possible to detect disease at the cellular level, before anatomical changes occur, which become more apparent in later stages of disease. Imaging the disease-related changes at the level of the cell enables early disease detection and a more sensitive means of monitoring disease progression and response to therapy compared with current imaging technologies.

Molecular Insight has five clinical-stage candidates in development. The Company’s oncology candidates include: Azedra? for treatment of pheochromocytoma and neuroblastoma, Onalta? for the treatment of metastatic carcinoid and pancreatic neuroendocrine tumors, Solazed?, which targets malignant metastatic melanoma, and Trofex? for the detection of metastatic prostate cancer. Zemiva?, the Company’s cardiology candidate, is being developed for the diagnosis of acute myocardial ischemia.

Molecular Insight is headquartered in Cambridge, Massachusetts. The Company’s Common Stock trades on the NASDAQ Global Market under the symbol “MIPI.”
?